- In January 2025, Intervacc AB (publ) received orders from Dechra Pharmaceuticals totaling approximately SEK 5.8 million. These orders are for Strangvac, a vaccine designed to protect horses from the highly contagious and severe infectious disease, strangles. The order covers vaccine vials for the UK, Germany, France, the Netherlands, Belgium, and Austria, with delivery expected within the next 3 to 4 months.
- In November 2024, Boehringer Ingelheim announced the launch of its latest advanced Marek’s disease vaccine in India. This next-generation vaccine provides enhanced protection through an innovative controlled attenuation process, ensuring an optimal balance between safety and efficacy. Marek’s disease continues to be a major challenge in Indian poultry, with outbreaks persisting despite widespread vaccination. This new vaccine addresses this issue with a groundbreaking serotype-1 construct, offering effective protection against the most virulent strains while maintaining safety.
- In September 2024, Elanco Animal Health Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved Zenrelia, a safe, highly effective, and convenient once-daily oral JAK inhibitor for managing pruritus (itching) associated with allergic dermatitis and controlling atopic dermatitis in dogs aged 12 months and older. The approval of Zenrelia marks a significant advancement in treating dogs with chronic, acute, or seasonal itching and inflammation, offering relief through a single, once-daily tablet from the start.
- In August 2024, Intervacc AB (publ) and the Karolinska Institute (KI) announced the extension of their collaboration to develop a new generation of animal health vaccines using recombinant fusion proteins. The three-year extension ensures that the research team at the Karolinska Institutet, led by Professor Birgitta Henriques Normark, will continue to be an integral part of the successful partnership between KI, the Swedish University of Agricultural Sciences (SLU), and Intervacc.
- In October 2023, the University of Saskatchewan's (USask) Vaccine and Infectious Disease Organization (VIDO) signed a memorandum of understanding (MOU) with the Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) at The Pirbright Institute. This MOU paves the way for expanded collaborations and training in vaccine manufacturing, aiming to drive innovations in animal health.
